Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Naporafenib · ERAS-254, LXH-254

Small molecule · Inhibitor of RAF kinases (pan-Raf) · developed by Novartis Pharmaceuticals

Phase 3 Most advanced trial
NVS Developer
1 Registered trials

What is Naporafenib?

Naporafenib (ERAS-254) is an orally available inhibitor of all members of the Raf serine/threonine kinase family. It binds Raf proteins and blocks Raf-mediated signaling through the Ras/Raf/MEK/ERK pathway, inhibiting proliferation of Raf-overexpressing tumor cells. It is being studied in advanced or metastatic NRAS-mutant melanoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
ERAS-254, LXH-254
Drug type
Small molecule
Targets
RAF kinases (pan-Raf)
Mechanism
Inhibitor of RAF kinases (pan-Raf)
Pathways
Ras/Raf/MEK/ERK signaling
Therapy area
Oncology
Developer
Novartis Pharmaceuticals (NVS)
Also in trials of
ERAS
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
15JL80DG6H

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06346067 Phase 3 Advanced or Metastatic NRAS-mutant Melanoma Active not recruiting ERAS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced or Metastatic NRAS-mutant Melanoma

More from Novartis Pharmaceuticals

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the NVS page.

Follow NVS, the company behind Naporafenib

See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.